PARIS, June 13 /CNW/ -- Seven-year rheumatoid arthritis (RA) data from
open-label extension studies show that treatment with Abbott's HUMIRA(R)
(adalimumab) resulted in clinical remission among long-standing RA patients
when used in combination with methotrexate (MTX). The percentage of patients
achieving clinical remission continued to increase after two or more years of
continuous treatment with combination therapy. These data were presented at
the European League Against Rheumatism (EULAR) annual meeting in Paris.
